一、前言 近年来，随着干细胞治疗、免疫细胞治疗和基因编辑等基础理论、技术手段和临床医疗探索研究的不断发展，细胞治疗产品为一些严重及难治性疾病提供了新的治疗思路与方法。为规范和...
发简信
IP属地：加州
-
细胞治疗产品研究与评价技术指导原则 （试行）
-
《细胞治疗产品研究与评价技术指导原则》（试行）相关问题解读
1.制定发布《细胞治疗产品研究与评价技术指导原则》的背景是什么？ 细胞治疗技术是目前国际医学前沿重点发展领域，它给一些人类疑难疾病的治疗提供了新的希望。近年来，细胞治疗领域不...
-
Singapore’s Tessa raises $80M for T cell therapy push
Emerging immuno-oncology player Tessa Therapeutics has raised $80 million in a financin...
-
Juno Therapeutics and Thermo Fisher Scientific Announce CAR T Manufacturing Partnership
WALTHAM, Mass.,Dec. 20, 2017/PRNewswire/ -- Juno Therapeutics (NASDAQ:JUNO) and Thermo ...
-
Juno Try to explain death related to CAR-T
The blood-brain barrier disruption appears to be “a unique mechanism within this settin...
-
WuXi AppTec Selected by IQVIA Stem Cell Center to Serve as GMP Manufacturer of Cell Therapies and others
PHILADELPHIA,Nov. 17, 2017/PRNewswire/ -- WuXi AppTec (WuXi), a leading global pharmace...
-
Seattle Children’s opens first pediatric CAR T-Cell trial dual targeting CD22 and CD19
Seattle Children’s has opened the first chimeric antigen receptor (CAR) T-cell immunoth...
-
FDA Approves Gazyva (CD-20 mab) For Advanced Follicular Lymphoma
The Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) in combinatio...
-
FDA Grants Bluebird BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma
The FDA has granted Bluebird bb2121 a breakthrough therapy designation for previously t...
-
CBMG Opens its New Shanghai GMP Facility and Joint Laboratory
SHANGHAI, China and CUPERTINO, Calif.,November 7, 2017/GlobeNewswire/ —Cellular Biomedi...
-
FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN
November 6, 2017 – New York (N.Y.)– Cellectis (Alternext: ALCLS - Nasdaq: CLLS) a clini...
-
Eureka is hiring
We have the following position open, if you are interested and feel it would be a good ...
-
Eutilex and Huahai Enter Immuno-Oncology Partnership
SEOUL, South Korea,Nov. 6, 2017/PRNewswire/ --Eutilex Co. Ltd. today announced that it ...
-
Servier and Pfizer to Announce UCART19 Data at ASHPreliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-...
-
CABS国际合作部招募志愿者/委员会委员湾区最大的华人生物协会CABS国际合作部招募志愿者/委员会委员， Chinese American Bio/Pharmaceutical Society是湾区最大的华人生物协...
